Indian vaccine maker Bharat Biotech said on Thursday it had invested $75 million in its first cell and gene therapy (CGT) facility in the southern Indian state of Telangana and expects its new ...

Hyderabad: Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and ...

Our Bureau, Bengaluru Thursday, March 20, 2025, 17:40 Hrs [IST] ...

Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...

The Adeno Associated Virus Vector Manufacturing market, valued at USD 1,148.4 million in 2024, is expected to register robust revenue CAGR of 19.6%.Request free copy of this report:  March 14, 2025 - ...

Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said that oncology and rare ...

By replacing the defective gene associated with Dravet syndrome in mice, scientists successfully alleviated symptoms without ...

University of Toronto researchers have discovered nine new genes used by bacteria to protect themselves against ...

In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...

Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...